MIDAS Project Publication Abstracts

Posternak, M.A., Zimmerman, M., Miller, I., & Keitner, G. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. American Journal of Psychiatry, 2005, 159, 191-200.

Objective: Antidepressant efficacy trials (AETs) employ multiple exclusion criteria that are designed primarily to maximize drug-placebo differences. These exclusion criteria were implemented prior to having undergone rigorous testing, however, and it is unclear whether they accomplish their intended goal. In the present report, we sought to review the current state of knowledge regarding treatment response rates in individuals who are typically excluded from AETs. Method: After reviewing 31 AETs published between 1994 and 1998, we identified 10 commonly used exclusion criteria. A computerized MEDLINE and manual search was then performed, and all studies evaluating the efficacy of antidepressant medications in populations of subjects typically excluded from AETs were reviewed. Results: Three exclusion criteria: short episode duration, mild severity of illness, and positive response during the placebo lead-in phase are utilized primarily to reduce placebo response rates. Of these, there exists only preliminary evidence suggesting that a short episode duration may be associated with less robust drug-placebo response rates. The 7 other exclusion criteria we identified including various psychiatric comorbidity, chronic duration of illness, medical comorbidity, and prior nonresponse to treatment are utilized because such individuals are believed to have lower response rates to somatic therapy. While often true, such individuals also appear to have lower response rates to placebo, and there is little evidence to suggest that drug-placebo differences are any less robust in these individuals. Conclusions: Studies to date suggest that many of the standard exclusion criteria currently being employed in AETs may not be achieving their intended goal. The practice of excluding subjects with particular clinical profiles, which greatly reduces the generalizability of AETs, appears to lack empirical support.

Back